Literature DB >> 8205528

Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

P F Robbins1, M el-Gamil, Y Kawakami, E Stevens, J R Yannelli, S A Rosenberg.   

Abstract

The observation that allogeneic melanoma cells matched for particular HLA class I alleles stimulate T-cells isolated from patients suggests that widely shared antigens exist on these tumors. A transient expression system was developed for screening a melanoma complementary DNA library using the highly transfectable human kidney cell line 293. Using this system, large numbers of complementary DNA clones can be rapidly screened for the expression of antigens which stimulate T-cells. Tumor-infiltrating lymphocytes from patient 888, which recognized melanoma in the context of HLA-A24, were used to screen a complementary DNA library made from the autologous melanoma. Our results demonstrate that these tumor-infiltrating lymphocytes recognize tyrosinase, a gene previously shown to be recognized by T-cells only in the context of HLA-A2. These data demonstrate that a single antigen can be recognized in the context of two different class I HLA alleles. In addition, this study suggests that recognition of tyrosinase by antigen-specific T-cells may be involved in tumor rejection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205528

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

2.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors:  T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.

Authors:  Kimberly R Lindsey; Linda Gritz; Richard Sherry; Andrea Abati; Patricia A Fetsch; Lisa C Goldfeder; Monica I Gonzales; Kimberly A Zinnack; Linda Rogers-Freezer; Leah Haworth; Sharon A Mavroukakis; Donald E White; Seth M Steinberg; Nicholas P Restifo; Dennis L Panicali; Steven A Rosenberg; Suzanne L Topalian
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

5.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

6.  Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.

Authors:  Y T Chen; E Stockert; A Jungbluth; S Tsang; K A Coplan; M J Scanlan; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 7.  Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.

Authors:  P Romero
Journal:  Springer Semin Immunopathol       Date:  1996

8.  Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Authors:  Shigui Zhu; Benoit J Van den Eynde; Pierre G Coulie; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

9.  Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.

Authors:  S J Orlow; V J Hearing; C Sakai; K Urabe; B K Zhou; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 10.  Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Authors:  M H Geukes Foppen; M Donia; I M Svane; J B A G Haanen
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.